-
Mashup Score: 67Fertility Preservation and Post-treatment Pregnancies in - 6 month(s) ago
Clinical Practice Guidelines – Fertility Preservation and Post-treatment Pregnancies in Post-pubertal Cancer Patients
Source: www.esmo.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice - Nature Cancer - 6 month(s) ago
In preclinical studies, Hutt, Loi and colleagues find that mice treated with checkpoint blockade have impaired ovarian function and reserve, associated with increased immune infiltrate, raising considerations about fertility implications for female patients.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue - 6 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Beyond #chemotherapy, we should highlight that we lack data on gonadotoxicity risk with the new targeted treatment options and #immunotherapy...we need more research efforts here https://t.co/nF3nl1RPBn #ESHREjc @maclaudiaa @ESHRE #oncofertility @OncoAlert https://t.co/pW8Ff7cMbi https://t.co/nRbmcLtnPg
-
-
Mashup Score: 11
BackgroundOffering ovarian function and/or fertility preservation strategies in premenopausal women with newly diagnosed breast cancer candidates to undergo chemotherapy is standard of care. However, few data are available on uptake and main reasons for refusing these options.MethodsThe PREFER study (NCT02895165) is an observational, prospective study enrolling premenopausal women with early breast cancer, aged between 18 and 45 years, candidates to receive (neo)adjuvant chemotherapy. Primary objective is to collect information on acceptance rates and reasons for refusal of the proposed strategies for ovarian function and/or fertility preservation available in Italy.ResultsAt the study coordinating center, 223 patients were recruited between November 2012 and December 2020. Median age was 38 years (range 24 – 45 years) with 159 patients (71.3%) diagnosed at ≤40 years. Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) was accepted by 58 out of 64 (90.6%)
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52
This cohort study assesses factors associated with chemotherapy-related amenorrhea and evaluates its association with long-term quality of life among premenopausal women with breast cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma - 7 month(s) ago
Cutaneous squamous cell carcinoma (CSCC) is the second most common malignancy [1]. The main risk factors are chronic sun exposure, age, fair skin phototype, and immunosuppression (immunosuppressive therapy for autoimmune disease, hematologic malignancy, solid organ transplantation and HIV infection) [1].
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46From Texas to Sweden, Medical Oncologist Gil Morgan Enjoys Connecting the Cancer Community - The ASCO Post - 7 month(s) ago
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert Network. Dr. Morgan has been Chair of the European Society for Medical Oncology (ESMO) Social Media Working Group and previously served on the ESMO Membership Committee and the Global Policy Committee, all for
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma - 7 month(s) ago
Cutaneous squamous cell carcinoma (CSCC) is the second most common malignancy [1]. The main risk factors are chronic sun exposure, age, fair skin phototype, and immunosuppression (immunosuppressive therapy for autoimmune disease, hematologic malignancy, solid organ transplantation and HIV infection) [1].
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6The OncoAlert Newsletter is NOW OUT Click to Register - 7 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6The OncoAlert Newsletter is NOW OUT Click to Register - 7 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Hem/OncsTweet
Yes, for ovarian function preservation should be offered (particularly in #BreastCancer) but it is not an alternative to cryopreservation procedures for patients interested in #fertilitypreservation…I follow this algorithm of @myESMO guidelines #ESHREjc https://t.co/sG9FOLFG5T https://t.co/zqiXJqxsPF https://t.co/cX8En3HiW5